BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//7.2.3.1//EN
TZID:Europe/Helsinki
X-WR-TIMEZONE:Europe/Helsinki
BEGIN:VEVENT
UID:374@inflames.utu.fi
DTSTART;TZID=Europe/Helsinki:20241212T130000
DTEND;TZID=Europe/Helsinki:20241212T140000
DTSTAMP:20241205T104305Z
URL:https://inflames.utu.fi/events/guest-seminar-dr-achim-doerner/
SUMMARY:InFLAMES guest seminar: Dr. Achim Doerner
DESCRIPTION:InFLAMES guest seminar: Dr. Achim Doerner\nScientific Director 
 for Antibody Discovery and Protein Engineering\, Merck Healthcare\n\nTitle
 : Therapeutic Antibody Hit Discovery\nWhen: Thu December 12th\, 2024 at 13
 :00–14:00\nWhere: Ministeri lecture room\, BioCity\, Tykistökatu 6\nHos
 t: Urpo Lamminmäki\, University of Turku\, Department of Life Technologie
 s\n\nAfter the seminar\, it is possible to have a one-on-one discussion wi
 th Dr. Doerner. If you are interested in having such a discussion\, please
  contact urpo.lamminmaki@utu.fi.\n\nAbout Dr. Achim Doerner:\n\nDr. Achim 
 Doerner serves as the Scientific director for antibody discovery and prote
 in engineering at Merck Healthcare in Darmstadt\, Germany\, one of the lea
 ding companies in the development of therapeutic antibodies.  A biochemis
 t by training\, Dr. Doerner has been designing and progressing bispecific 
 antibodies and antibody-drug conjugates through preclinical development fo
 r over a decade. Complementary interests are protein engineering and techn
 ology development for plate-based bispecific antibody screening and mammal
 ian libraries for microfluidic functional screens.\n\nSelected publication
 s:\n\nSlavny\, P\; Hegde\, M\; Doerner\, A\; Parthiban\, K\; McCafferty\, 
 J\; Zielonka\, S\; Hoet\, R Advancements in mammalian display technology f
 or therapeutic antibody development and beyond: current landscape\, challe
 nges\, and future prospects. Front. Immunol.\, 2024\, 24\, 1469329\, https
 ://doi.org/10.3389/fimmu.2024.1469329\n\nEvers\, A.\; Krah\, S.\; Demir\, 
 D.\; Gaa\, R.\; Elter\, D.\; Schroeter\, C.\; Zielonka\, S.\; Rasche\, N.\
 ; Dotterweich\, J.\; Knuehl\, C.\; Doerner\, A. Engineering Hydrophobicity
  and Manufacturability for Optimized Biparatopic Antibody-Drug Conjugates 
 Targeting c-MET. MAbs 2024\, 16\, 2302386\, doi:10.1080/19420862.2024.2302
 386.\n\nBarron\, N.\; Dickgiesser\, S.\; Fleischer\, M.\; Bachmann\, A.-N.
 \; Klewinghaus\, D.\; Hannewald\, J.\; Ciesielski\, E.\; Kusters\, I.\; Ha
 mmann\, T.\; Doerner\, A. A Generic Approach for Miniaturized Unbiased Hig
 h-Throughput Screens of Bispecific Antibodies and Biparatopic Antibody-Dru
 g Conjugates. Int. J. Mol. Sci. 2024\, 25\, doi:10.3390/ijms25042097.\n\nL
 ipinski\, B.\; Unmuth\, L.\; Arras\, P.\; Becker\, S.\; Bauer\, C.\; Tolei
 kis\, L.\; Krah\, S.\; Doerner\, A.\; Yanakieva\, D.\; Boje\, A.S.\; et al
 . Generation and Engineering of Potent Single Domain Antibody-Based Bispec
 ific IL-18 Mimetics Resistant to IL-18BP Decoy Receptor Inhibition. MAbs 2
 023\, 15\, 2236265\, doi:10.1080/19420862.2023.2236265.\n\nGaa\, R.\; Maye
 r\, H.M.\; Noack\, D.\; Doerner\, A. Efficient Microfluidic Downstream Pro
 cesses for Rapid Antibody Hit Confirmation. Methods Mol. Biol. 2023\, 2681
 \, 327–341\, doi:10.1007/978-1-0716-3279-6_18.
ATTACH;FMTTYPE=image/jpeg:https://inflames.utu.fi/wp-content/uploads/Achim
 -Doerner.jpg
CATEGORIES:Events in English,Tapahtumat
END:VEVENT
BEGIN:VTIMEZONE
TZID:Europe/Helsinki
X-LIC-LOCATION:Europe/Helsinki
BEGIN:STANDARD
DTSTART:20241027T030000
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
END:STANDARD
END:VTIMEZONE
END:VCALENDAR